CYTK Aficamten data support FDA submission in non-obstructive HCM
CYTK says Aficamten showed significant, broad clinical benefit and safety in non-obstructive HCM, supporting an FDA submission.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.